Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG005 in Advanced Solid Tumors
NCT06927687Phase 2Active, not recruiting
- Sponsor
- Zelgen
- Start
- Jun 2025
- Primary completion
- May 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilvanstomig in solid tumor, sponsored by Zelgen. Primary endpoint: Objective Response Rate at 2 years. Started Jun 2025; status: active, not recruiting.
02
Drugs
nilvanstomig
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06927687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06927687.